Outcomes of Patients With New Left Bundle Branch Block Following Transcatheter Aortic Valve Replacement: Insights From the NCDR STS/ACC TVT Registry
18 min.
Atrioventricular Conduction System Changes During Transcatheter Aortic Valve Replacement (TAVR): Anatomic and Electrophysiologic Predictors of Heart Block in Prospective 400 Patient EPS/TAVR Study
22 min.
Trancatheter Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis and Small Aortic Annuli: A Randomized Clinical Trial (the VIVA Trial)
21 min.
Cerebral Microbleeds During Transcatheter Aortic Valve Replacement: A Prospective Magnetic Resonance Imaging Study Cohort
10 min.
Cardiac Output, Cerebral Blood Flow and Cognitive Functioning in Patients Undergoing Transcatheter Aortic Valve Implantation
9 min.
Prophylactic Antithrombotic Therapy After TAVR
12 min.
Pharmacotherapy to Slow AS Progression and Protect the Heart
9 min.
EVOLVED: CMR As an Early Marker of Risk
6 min.
Moderate AS With Heart Failure: TAVR UNLOAD
4 min.
Moderate AS With Cardiac Damage: The PROGRESS Trial
5 min.
Moderate AS With Cardiac Damage: The EXPAND TAVR II Trial
8 min.
TAVR vs SAVR in Low Gradient AS: Evidence Updates
18 min.
Five-year Echocardiographic Outcomes From The PARTNER 3 Low-risk Randomized Trial
17 min.
Importance of Patient Reported Outcomes
14 min.
An Echo Deep Dive of the PARTNER 5-Year Study
13 min.
Important Secondary Endpoints From the PARTNER 3 5-YEAR STUDY
18 min.
Perspectives on Mortality in the PARNTER 5-Year Study
15 min.
ALIGN-AR Trial: Initial Outcomes of the JenaValve Trilogy Transcatheter Aortic Valve Replacement in High Risk Patients With Symptomatic Severe Native Aortic Regurgitation
16 min.
Four-Year Outcomes From the EVOLUT Low Risk Trial
19 min.
Five-Year Clinical and Echocardiographic Outcomes From The PARTNER 3 Low-Risk Randomized Trial
23 min.
Comparison of Two Self-Expanding Transcatheter Heart Valves for Degenerated Surgical Bioprostheses: The AVENGER Multi-Center Registry
12 min.
Moderate AS With Heart Failure: UNLOAD and Beyond
9 min.
Prognostic Value of Tricuspid Valve Gradient After Transcatheter Edge-To-Edge Repair: Insights from the TriValve Registry
9 min.
SPOTLIGHT LECTURE: Failed TAVR Management -Lessons Learned From Registry Experiences
14 min.
Clinical Data for the ACURATE Platform
16 min.
Update From the Clinical Trials and Where I Would and Wouldn’t Use It
14 min.
Update From the Clinical Trials and Where I Would and Wouldn’t Use It
15 min.
Progress in Self-Expanding TAVR: OPTIMIZE PRO and the Evolut Fx
17 min.
Progress in Balloon-Expandable TAVR: SAPIEN X4 and the ALLIANCE Trial
8 min.
Pharmacotherapy to Prevent Calcific Aortic Stenosis: Novel Targets and Novel Study Methodologies
9 min.
How Do We Communicate Known vs Uncertain Risks and Benefits of TAVR to Younger (<65 yo) Patients?
14 min.
SPOTLIGHT LECTURE Staging of Aortic Stenosis According to Cardiac Dysfunction: Recent Updates
17 min.
Using CMR Imaging to Identify High-Risk Severe AS Patients (Introduction to the EVOLVED Study)
5 min.
Sensor-Guided TAVR Initial experience with the SavvyWire: Post-Market Registry of the First 60 Cases
7 min.
Safety and Efficacy of Cerebral Embolic Protection Systems in Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-analysis
18 min.
SPOTLIGHT INNOVATION LECTURE: The CEP Paradox: Reconciling Clinical Evidence, Patient’s Expectations and Future Technological Developments
8 min.
ShortCut Dedicated Aortic Leaflet Splitting Device: Clinical Experience and Emerging Indications
14 min.
Can Scoring the Calcified Aortic Valve Defer the Need for Permanent Implant (Leaflex): Technology and Clinical Update
12 min.
Aortic Valve Lithotripsy Before TAVR: Early Human Clinical Experience
6 min.
TAVR Explant: What Every Interventionalist (and Surgeon) Needs to Know
8 min.
Bioprosthetic Valve Failure and Durability—Does TAVR Really Outperform SAVR?
8 min.
Surgical ADVANCEMENTS in Aortic Valve Regurgitation: When to… Repair vs. Ross vs. Replace with Root Management?
10 min.
Intersection of Guidelines and Clinical practice : Meaningful Guardrails Provide a Necessary Framework
7 min.
Update on the Evidence – Registries are Enough
6 min.
Optimal Anti-Thrombotic Therapy After TAVR – Updates and Controversies
10 min.